Journal article
PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer
IJ Majewski, P Nuciforo, L Mittempergher, AJ Bosma, H Eidtmann, E Holmes, C Sotiriou, D Fumagalli, J Jimenez, C Aura, L Prudkin, MC Díaz-Delgado, L De la Peña, S Loi, C Ellis, N Schultz, E De Azambuja, N Harbeck, M Piccart-Gebhart, R Bernards Show all
Journal of Clinical Oncology | AMER SOC CLINICAL ONCOLOGY | Published : 2015
Abstract
Purpose: We investigated whether mutations in the gene encoding the phosphatidylinositol 3-kinase (PI3K) catalytic subunit (PIK3CA) correlates with response to neoadjuvant human epidermal growth factor receptor 2 (HER2) -targeted therapies in patients with breast cancer. Patients and Methods: Baseline tissue biopsies were available from patients with HER2-positive early breast cancer who were enrolled onto the Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimization trial (NeoALTTO). Activating mutations in PIK3CA were identified using mass spectrometry-based genotyping. Results: PIK3CA mutations were identified in 23% of HER2-positive breast tumors, and these mutations were associate..
View full abstractGrants
Awarded by GlaxoSmithKline
Funding Acknowledgements
The Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimization trial was sponsored by GlaxoSmithKline and conducted in collaboration with the Breast International Group and by the Spanish Breast Cancer Cooperative Group SOLTI. The BrEAST Data Center was responsible for data management, and Frontier Science was responsible for statistical analysis.